Dec 28, 2025 • MarketBeat
BULLISH
Harbor Capital Advisors Inc. Buys Shares of 59,801 ADMA Biologics Inc $ADMA
Harbor Capital Advisors Inc. has acquired 59,801 shares of ADMA Biologics Inc. in the third quarter, valued at approximately $877,000. This move aligns with increased institutional ownership of ADMA, which stands at around 75.7%, and reflects strong financial performance by the biotechnology company including 12% year-over-year revenue growth and a 42.87% net margin. Analysts currently rate ADMA with a "Buy" consensus and an average target price of $28.50.
Dec 27, 2025 • MarketBeat
BULLISH
Rice Hall James & Associates LLC Has $4.75 Million Stake in ADMA Biologics Inc $ADMA
Rice Hall James & Associates LLC significantly reduced its stake in ADMA Biologics Inc by 17.1%, selling 66,962 shares but still retaining 323,653 shares valued at approximately $4.75 million. Despite this, institutional investors collectively own 75.68% of ADMA Biologics. The company reported strong financial results in its last quarter with $0.16 EPS and $134.22 million revenue, leading analysts to maintain a "Buy" rating with a consensus target price of $28.50.
Dec 23, 2025 • Sahm
BULLISH
Assessing ADMA Biologics (ADMA) Valuation After Its Upgraded 2025 Revenue Guidance
ADMA Biologics recently raised its 2025 revenue guidance to $510 million, indicating strong growth momentum with a 14% one-month share price return and over 430% total shareholder return in three years. Despite significant past gains, the company is considered approximately 28.1% undervalued with a narrative fair value of $27.25, supported by long-term growth prospects, improved liquidity from debt refinancing, and potential for enhanced free cash flow and EPS. However, its valuation depends on successfully scaling its yield enhancement process and navigating competition and regulation within its specialized IVIG portfolio.
Dec 22, 2025 • MarketBeat
BULLISH
Texas Permanent School Fund Corp Has $1.87 Million Holdings in ADMA Biologics Inc $ADMA
The Texas Permanent School Fund Corp recently decreased its stake in ADMA Biologics Inc. by 39.3%, now holding 102,932 shares valued at approximately $1.87 million. Despite this, other major institutions significantly increased their positions, raising institutional ownership to 75.68%. Analysts maintain a "Buy" rating for ADMA, with a consensus price target of $28.50, following the company's meeting of EPS estimates and a 12% year-over-year revenue increase in its latest quarter.
Dec 21, 2025 • Yahoo Finance
SOMEWHAT-BULLISH
ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance
ADMA Biologics (NASDAQ:ADMA) has updated its 2025 revenue guidance, projecting total revenue of $510 million, an increase from the previous guidance of over $500 million. The company also adjusted its 2025 adjusted net income modestly to $158 million due to a higher effective tax rate. ADMA Biologics specializes in plasma-derived biologics for immune deficiencies and infectious diseases.
Dec 21, 2025 • Insider Monkey
BULLISH
ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance
ADMA Biologics (NASDAQ:ADMA) has updated its 2025 revenue guidance to $510 million, an increase from the previous guidance of over $500 million. The company also adjusted its 2025 adjusted net income to $158 million due to a higher effective tax rate. ADMA Biologics specializes in developing and marketing plasma-derived biologics for immune deficiencies and infectious diseases.